Kamada Ltd ( (KMDA) ) has released its Q1 earnings. Here is a breakdown of the information Kamada Ltd presented to its investors.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Kamada Ltd. is a global biopharmaceutical company specializing in specialty plasma-derived therapies for rare and serious conditions, with a focus on organic growth, business development, and innovative clinical trials.
Kamada Ltd. reported a strong financial performance for the first quarter of 2025, highlighted by a 17% increase in revenues and a 54% rise in adjusted EBITDA compared to the previous year. The company continues to demonstrate robust growth through its diverse product portfolio and strategic management.
Key financial metrics for the quarter include total revenues of $44.0 million and an adjusted EBITDA of $11.6 million. Kamada also expanded its plasma collection operations with a new site in San Antonio, Texas, and launched a post-marketing research program for CYTOGAM®. The company maintains a strong financial position to pursue mergers, acquisitions, and in-licensing opportunities.
Looking ahead, Kamada reiterates its full-year guidance for 2025, expecting double-digit profitable growth. The company remains committed to its strategic growth pillars, including advancing its Phase 3 Inhaled AAT program and expanding its commercial operations.